CN115006363A - A kind of oyster calcium carbonate chewable tablet and preparation method thereof - Google Patents
A kind of oyster calcium carbonate chewable tablet and preparation method thereof Download PDFInfo
- Publication number
- CN115006363A CN115006363A CN202210726510.1A CN202210726510A CN115006363A CN 115006363 A CN115006363 A CN 115006363A CN 202210726510 A CN202210726510 A CN 202210726510A CN 115006363 A CN115006363 A CN 115006363A
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- oyster calcium
- preparation
- citric acid
- chewable tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000237502 Ostreidae Species 0.000 title claims abstract description 88
- 235000020636 oyster Nutrition 0.000 title claims abstract description 88
- 229940041917 calcium carbonate chewable tablet Drugs 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 117
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 103
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 51
- 239000011248 coating agent Substances 0.000 claims abstract description 35
- 238000000576 coating method Methods 0.000 claims abstract description 35
- 238000005469 granulation Methods 0.000 claims abstract description 23
- 230000003179 granulation Effects 0.000 claims abstract description 23
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000008187 granular material Substances 0.000 claims description 53
- 235000010216 calcium carbonate Nutrition 0.000 claims description 48
- 229960003563 calcium carbonate Drugs 0.000 claims description 48
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 33
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
- 229960003943 hypromellose Drugs 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000000576 food coloring agent Substances 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000686 essence Substances 0.000 claims description 9
- 238000002955 isolation Methods 0.000 claims description 9
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 9
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 9
- 239000012752 auxiliary agent Substances 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 7
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 7
- 229940073490 sodium glutamate Drugs 0.000 claims description 7
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000009475 tablet pressing Methods 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 229960005069 calcium Drugs 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 229960000943 tartrazine Drugs 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000003837 high-temperature calcination Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明涉及医药制剂领域,尤其涉及一种牡蛎碳酸钙咀嚼片及其制备方法。The invention relates to the field of pharmaceutical preparations, in particular to an oyster calcium carbonate chewable tablet and a preparation method thereof.
背景技术Background technique
牡蛎碳酸钙是海洋生物牡蛎的壳为原料,经高温煅烧电解活化制备而成,牡蛎壳中含90%以上的碳酸钙,外观呈白色粉末状,含丰富的钙和人体所需的锰、锌、硅、磷等人体所需要的微量元素,牡蛎碳酸钙在溶解度与吸收方面均优于传统钙剂。牡蛎碳酸钙又称“活性钙”,作为补钙剂最早起源于日本,是具有生物活性和化学活性的优良天然钙源。如今牡蛎碳酸钙广泛应用于欧美各国,已收载于中国、美国、英国、日本药典,临床上用作补钙制剂。Oyster calcium carbonate is the shell of marine organism oyster as raw material, which is prepared by high temperature calcination and electrolytic activation. The oyster shell contains more than 90% calcium carbonate, and its appearance is white powder, rich in calcium and manganese and zinc required by the human body. , silicon, phosphorus and other trace elements needed by the human body, oyster calcium carbonate is better than traditional calcium in solubility and absorption. Oyster calcium carbonate, also known as "active calcium", originated in Japan as a calcium supplement and is an excellent natural calcium source with biological activity and chemical activity. Today, oyster calcium carbonate is widely used in Europe and the United States, and has been included in the Chinese, American, British, and Japanese Pharmacopoeia, and is clinically used as a calcium supplement.
牡蛎碳酸钙咀嚼片,其药理作用是其中的钙参与骨骼的形成与骨折后骨组织的再建,维持神经传递和肌肉收缩,降低毛细血管的渗透性,维持其正常渗透压,还参与凝血机制,保持血液酸碱平衡等。适应症为用于儿童、妊娠或哺乳期妇女、绝经期妇女以及老年人补充钙质。目前牡蛎碳酸钙咀嚼片中每片含牡蛎碳酸钙按钙计50毫克,辅料为枸橼酸、蔗糖、淀粉、蛋白糖、硬脂酸镁、色素(柠檬黄)、羟丙基纤维素。Oyster calcium carbonate chewable tablet, its pharmacological effect is that calcium in it participates in the formation of bones and the reconstruction of bone tissue after fracture, maintains nerve transmission and muscle contraction, reduces the permeability of capillaries, maintains its normal osmotic pressure, and also participates in coagulation mechanism, Maintain blood acid-base balance, etc. Indications are calcium supplementation for children, pregnant or lactating women, menopausal women and the elderly. At present, each oyster calcium carbonate chewable tablet contains 50 mg of oyster calcium carbonate in terms of calcium, and the excipients are citric acid, sucrose, starch, protein sugar, magnesium stearate, pigment (tartrazine), and hydroxypropyl cellulose.
但现有的牡蛎碳酸钙咀嚼片普遍采用湿法制粒,其处方中的枸橼酸容易吸潮引起与碳酸钙的反应,造成质量问题,枸橼酸作为矫味剂以及促进钙吸收的酸剂,对于该咀嚼片作用重大,无法轻易取代。因此,有必要对现有的牡蛎碳酸钙咀嚼片生产工艺进行改进创新。But the existing oyster calcium carbonate chewable tablets generally adopt wet granulation, the citric acid in its prescription is easy to absorb moisture and cause a reaction with calcium carbonate, causing quality problems, citric acid is used as a flavoring agent and an acid agent for promoting calcium absorption , has a significant effect on the chewable tablet and cannot be easily replaced. Therefore, it is necessary to improve and innovate the existing production process of oyster calcium carbonate chewable tablets.
发明内容SUMMARY OF THE INVENTION
本发明为解决现有牡蛎碳酸钙咀嚼处方中枸橼酸容易吸潮引起与碳酸钙的反应的问题,提出一种牡蛎碳酸钙咀嚼片及其制备方法。In order to solve the problem that citric acid easily absorbs moisture and causes a reaction with calcium carbonate in the existing oyster calcium carbonate chewing prescription, the invention provides an oyster calcium carbonate chewable tablet and a preparation method thereof.
为实现上述目的,本发明采用以下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
本发明的第一个方面是提供一种牡蛎碳酸钙咀嚼片的制备方法,其核心方案是,以羟丙甲纤维素(HPMC)的乙醇溶液为粘合剂对牡蛎碳酸钙、交联聚维酮和微晶纤维素的混合物进行制粒并包衣,并将包衣后的牡蛎碳酸钙颗粒与含有枸橼酸和辅料的枸橼酸颗粒混匀后压片,即得。The first aspect of the present invention is to provide a preparation method of an oyster calcium carbonate chewable tablet. The mixture of ketone and microcrystalline cellulose is granulated and coated, and the coated oyster calcium carbonate granules are mixed with citric acid granules containing citric acid and auxiliary materials, and then compressed into tablets.
优选地,所述牡蛎碳酸钙颗粒的制备,包括如下步骤:Preferably, the preparation of described oyster calcium carbonate particles comprises the steps:
以处方量的羟丙甲纤维素(HPMC)的乙醇溶液为粘合剂,对牡蛎碳酸钙、交联聚维酮和微晶纤维素的混合物进行顶喷制粒;Taking the ethanolic solution of the hypromellose (HPMC) of recipe quantity as binder, the mixture of oyster calcium carbonate, crospovidone and microcrystalline cellulose is top-sprayed and granulated;
以处方量的羟丙甲纤维素(HPMC)或其与食用色素的乙醇溶液为包衣液,对顶喷颗粒进行底喷包衣,得牡蛎碳酸钙颗粒。Taking the hypromellose (HPMC) of recipe quantity or its ethanol solution with food coloring as coating liquid, the top spray granules are carried out bottom spray coating to obtain oyster calcium carbonate granules.
较为优选地,所述牡蛎碳酸钙在制粒包衣前经微粉化处理,并过200目筛;且包衣后的所述牡蛎碳酸钙颗粒过16目筛。More preferably, the oyster calcium carbonate is subjected to micronization treatment before granulation and coating, and passed through a 200-mesh sieve; and the coated oyster calcium carbonate particles are passed through a 16-mesh sieve.
优选地,所述乙醇溶液的浓度为30-70%。Preferably, the concentration of the ethanol solution is 30-70%.
较为优选地,所述乙醇溶液的浓度为40-65%。More preferably, the concentration of the ethanol solution is 40-65%.
更为优选地,所述乙醇溶液的浓度为55-60%。More preferably, the concentration of the ethanol solution is 55-60%.
优选地,所述枸橼酸颗粒的制备,包括如下步骤:Preferably, the preparation of the citric acid granules comprises the following steps:
将处方量的枸橼酸与甘露醇、蔗糖混合后,然后加入处方量的含有助剂的乙醇溶液进行制粒,经烘干后,得枸橼酸颗粒;After mixing the citric acid of the recipe quantity with mannitol and sucrose, then adding the ethanol solution containing the auxiliary agent in the recipe quantity to carry out granulation, after drying, the citric acid granules are obtained;
其中,所述助剂选自食用香精、食用色素、谷氨酸钠中的一种或几种的组合。Wherein, the auxiliary agent is selected from one or a combination of food essence, food coloring and sodium glutamate.
较为优选地,所述枸橼酸、甘露醇和蔗糖在制粒前经粉碎处理,并过80目筛;且制粒后的所述枸橼酸颗粒过16目筛。More preferably, the citric acid, mannitol and sucrose are pulverized and passed through an 80-mesh sieve before granulation; and the citric acid particles after granulation are passed through a 16-mesh sieve.
较为优选地,所述烘干工艺为:采用70-75℃的热风,烘干3-7h。Preferably, the drying process is as follows: using hot air at 70-75° C., drying for 3-7 hours.
更为优选地,所述烘干工艺为:采用72-74℃的热风,烘干4-6h。More preferably, the drying process is as follows: using hot air at 72-74° C., drying for 4-6 hours.
优选地,所述压片工艺为:Preferably, the tableting process is:
将处方量的牡蛎碳酸钙颗粒、枸橼酸颗粒与润滑剂混合均匀后再进行压片;The oyster calcium carbonate granules, citric acid granules and lubricants of the recipe quantity are evenly mixed and then pressed into tablets;
其中,所述润滑剂选自滑石粉和硬脂酸镁中的一种或两种的组合。Wherein, the lubricant is selected from one or a combination of talc and magnesium stearate.
更为优选地,所述牡蛎碳酸钙咀嚼片的制备方法,具体包括如下步骤:More preferably, the preparation method of described oyster calcium carbonate chewable tablet specifically comprises the steps:
(一)牡蛎碳酸钙颗粒的制备(1) Preparation of oyster calcium carbonate particles
a、将牡蛎碳酸钙经过微粉化处理,过200目筛;a. The oyster calcium carbonate is subjected to micronization treatment and passed through a 200-mesh sieve;
b、将羟丙甲纤维素(HPMC)溶于乙醇溶液中,过80目筛,得粘合剂,备用;B, hypromellose (HPMC) is dissolved in ethanol solution, sieves 80 meshes, obtains adhesive, standby;
c、将羟丙甲纤维素(HPMC)、食用色素溶于乙醇溶液中,过80目筛,得隔离包衣液,备用;C, hypromellose (HPMC), food coloring are dissolved in ethanol solution, cross 80 mesh sieves, obtain isolation coating liquid, for subsequent use;
d、将处方量的牡蛎碳酸钙、微晶纤维素、交联聚维酮混匀后置于制粒包衣锅中,喷入粘合剂,进行顶喷制粒;D, the oyster calcium carbonate, microcrystalline cellulose, crospovidone of the recipe quantity are mixed and placed in the granulation coating pot, sprayed into the adhesive, and carried out top spray granulation;
e、将顶喷制得的物料过20目筛网,剔除大于20目颗粒;e. Pass the material obtained by top spraying through a 20-mesh screen to remove particles larger than 20-mesh;
f、将颗粒置于制粒包衣锅中,喷入隔离包衣液,底喷包衣;f. The granules are placed in the granulation coating pot, sprayed into the isolation coating liquid, and the bottom is sprayed for coating;
g、将包衣后的物料过16目筛网,剔除大于16目颗粒,得颗粒I;g, the material after coating is crossed 16 mesh screen, rejects more than 16 mesh granules, obtains granule I;
(二)枸橼酸颗粒的制备(2) Preparation of Citric Acid Granules
a、将处方量的枸橼酸、甘露醇、蔗糖粉碎过80目筛;A, the citric acid, mannitol and sucrose of the recipe quantity are pulverized through 80 mesh sieves;
b、将处方量的食用香精、食用色素、谷氨酸钠溶于乙醇溶液中,备用;b. Dissolve the edible essence, food coloring, and sodium glutamate of the prescription in the ethanol solution for subsequent use;
c、将处理后的枸橼酸、甘露醇、蔗糖置入高速制粒机中,慢速搅拌1-3分钟内,加入含有助剂的乙醇溶液,快速制粒2-5分钟;c. Put the treated citric acid, mannitol and sucrose into a high-speed granulator, stir at a slow speed for 1-3 minutes, add an ethanol solution containing an auxiliary agent, and quickly granulate for 2-5 minutes;
d、将湿粒摊盘,送进烘房,采用70~75℃热风干燥3-7小时;d. Spread the wet granules on a plate, send them to the drying room, and dry them with hot air at 70-75°C for 3-7 hours;
e、物料过16目筛网,剔除大于16目颗粒,得颗粒II;e. The material is passed through a 16-mesh screen, and the particles larger than 16-mesh are removed to obtain particle II;
(三)压片(3) Tablet pressing
将颗粒I、颗粒II、滑石粉和硬脂酸镁混匀后压片,即得牡蛎碳酸钙咀嚼片。The granules I, the granules II, the talc and the magnesium stearate are mixed and pressed into tablets to obtain oyster calcium carbonate chewable tablets.
本发明的第二个方面是提供一种适用于上述所述制备方法的牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:A second aspect of the present invention is to provide a chewable oyster calcium carbonate chewable tablet suitable for the above-mentioned preparation method, which comprises the following components in a prescription quantity (kg) per 10,000 tablets:
优选地,所述制备方法的牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Preferably, the oyster calcium carbonate chewable tablet of the preparation method, in terms of the prescription quantity (kg) per 10,000 tablets, comprises the following components:
优选地,所述制备方法的牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Preferably, the oyster calcium carbonate chewable tablet of the preparation method, in terms of the prescription quantity (kg) per 10,000 tablets, comprises the following components:
优选地,所述食用香精采用甜橙油、柠檬油、柑橘油中的一种或几种;优选地,所述食用香精采用甜橙油。Preferably, the edible essence adopts one or more of sweet orange oil, lemon oil, and citrus oil; preferably, the edible essence adopts sweet orange oil.
优选地,所述食用色素采用胭脂红、柠檬黄、亮蓝中的一种或几种,所述食用色素不是方案必须,根据不同色素,用量不同,如胭脂红用0.5g/万片,亮蓝用0.1g/万片,柠檬黄用0.7g/万片,然后根据物料比例分别加入颗粒I和颗粒II。Preferably, the food coloring adopts one or more of carmine, lemon yellow, and bright blue. The food coloring is not necessary for the plan, and the dosage is different according to different pigments. Blue uses 0.1g/10,000 pieces, tartrazine uses 0.7g/10,000 pieces, and then add granules I and granules II according to the material ratio.
本发明采用上述技术方案,与现有技术相比,具有如下技术效果:The present invention adopts the above-mentioned technical scheme, compared with the prior art, has the following technical effects:
本发明先采用羟丙甲纤维素(HPMC)的乙醇溶液为粘合剂对牡蛎碳酸钙、交联聚维酮和微晶纤维素的混合物进行制粒,然后采用羟丙甲纤维素(HPMC)的乙醇溶液为包衣液对颗粒进行包衣,制得牡蛎碳酸钙颗粒;最后将牡蛎碳酸钙颗粒与湿法制粒的枸橼酸颗粒进行混合压片。即采用羟丙甲纤维素(HMPC)制粒包衣保护牡蛎碳酸钙,以隔离枸橼酸,避免枸橼酸容易吸潮引起与碳酸钙的反应,有效克服了现有牡蛎碳酸钙咀嚼片因吸潮而引起的质量问题。In the present invention, the ethanol solution of hypromellose (HPMC) is used as a binder to granulate the mixture of oyster calcium carbonate, crospovidone and microcrystalline cellulose, and then hypromellose (HPMC) is used for granulation. The ethanol solution of the oyster is used as a coating solution to coat the granules to obtain the oyster calcium carbonate granules; finally, the oyster calcium carbonate granules and the wet granulated citric acid granules are mixed and compressed into tablets. That is, hypromellose (HMPC) granulation coating is used to protect the oyster calcium carbonate, so as to isolate the citric acid and avoid the reaction with the calcium carbonate caused by the easy moisture absorption of the citric acid. Quality problems caused by moisture absorption.
且值得注意的是,本发明中的交联聚维酮(PVPP)是作崩解剂用的,此处用崩解剂是因为隔离层包衣会影响溶出速率,加崩解剂可以加速主药在口腔内释放,另外本发明的粘合剂和隔离层包衣材料均采用羟丙甲纤维素(HPMC)。And it is worth noting that the crospovidone (PVPP) in the present invention is used as a disintegrating agent, and the disintegrating agent is used here because the isolation layer coating will affect the dissolution rate, and adding a disintegrating agent can accelerate the main body. The drug is released in the oral cavity, and the adhesive and the barrier layer coating material of the present invention are both hypromellose (HPMC).
具体实施方式Detailed ways
下面通过具体实施例对本发明进行详细和具体的介绍,以使更好的理解本发明,但是下述实施例并不限制本发明范围。The present invention will be described in detail and concretely below through specific embodiments, so as to make the present invention better understood, but the following embodiments do not limit the scope of the present invention.
实施例1牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Embodiment 1 The oyster calcium carbonate chewable tablet, according to the prescription amount (kg) per 10,000 tablets, includes the following components:
牡蛎碳酸钙咀嚼片的制备,包括如下步骤:The preparation of oyster calcium carbonate chewable tablet includes the following steps:
(一)牡蛎碳酸钙颗粒的制备(1) Preparation of oyster calcium carbonate particles
a、将牡蛎碳酸钙经过微粉化处理,过200目筛;a. The oyster calcium carbonate is subjected to micronization treatment and passed through a 200-mesh sieve;
b、将羟丙甲纤维素(HPMC)溶于乙醇溶液中,过80目筛,得粘合剂,备用;B, hypromellose (HPMC) is dissolved in ethanol solution, sieves 80 meshes, obtains adhesive, standby;
c、将羟丙甲纤维素(HPMC)、食用色素溶于乙醇溶液中,过80目筛,得隔离包衣液,备用;C, hypromellose (HPMC), food coloring are dissolved in ethanol solution, cross 80 mesh sieves, obtain isolation coating liquid, for subsequent use;
d、将处方量的牡蛎碳酸钙、微晶纤维素、交联聚维酮混匀后置于制粒包衣锅中,喷入粘合剂,进行顶喷制粒;D, the oyster calcium carbonate, microcrystalline cellulose, crospovidone of the recipe quantity are mixed and placed in the granulation coating pot, sprayed into the adhesive, and carried out top spray granulation;
e、将顶喷制得的物料过20目筛网,剔除大于20目颗粒;e. Pass the material obtained by top spraying through a 20-mesh screen to remove particles larger than 20-mesh;
f、将颗粒置于制粒包衣锅中,喷入隔离包衣液,底喷包衣;f. The granules are placed in the granulation coating pot, sprayed into the isolation coating liquid, and the bottom is sprayed for coating;
g、将包衣后的物料过16目筛网,剔除大于16目颗粒,得颗粒I;g, the material after coating is crossed 16 mesh screen, rejects more than 16 mesh granules, obtains granule I;
(二)枸橼酸颗粒的制备(2) Preparation of Citric Acid Granules
a、将处方量的枸橼酸、甘露醇、蔗糖粉碎过80目筛;A, the citric acid, mannitol and sucrose of the recipe quantity are pulverized through 80 mesh sieves;
b、将处方量的食用香精、食用色素、谷氨酸钠溶于乙醇溶液中,备用;b. Dissolve the edible essence, food coloring, and sodium glutamate of the prescription in the ethanol solution for subsequent use;
c、将处理后的枸橼酸、甘露醇、蔗糖置入高速制粒机中,慢速搅拌2分钟内,加入含有助剂的乙醇溶液,快速制粒3分钟;c. Put the treated citric acid, mannitol and sucrose into a high-speed granulator, stir at a slow speed for 2 minutes, add an ethanol solution containing an auxiliary agent, and quickly granulate for 3 minutes;
d、将湿粒摊盘,送进烘房,采用70~75℃热风干燥5小时;d. Spread the wet granules on a plate, send them to the drying room, and dry them with hot air at 70-75°C for 5 hours;
e、物料过16目筛网,剔除大于16目颗粒,得颗粒II;e. The material is passed through a 16-mesh screen, and the particles larger than 16-mesh are removed to obtain particle II;
(三)压片(3) Tablet pressing
将颗粒I、颗粒II、滑石粉和硬脂酸镁混匀后压片,即得牡蛎碳酸钙咀嚼片1。Mix Granule I, Granule II, talc and magnesium stearate and press into tablets to obtain oyster calcium carbonate chewable tablet 1.
实施例2牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Embodiment 2 Oyster calcium carbonate chewable tablet, by every ten thousand pieces of prescription quantity (kg), comprises the following components:
该牡蛎碳酸钙咀嚼片的制备工艺,与实施例1的制备工艺相同。The preparation process of the oyster calcium carbonate chewable tablet is the same as that of Example 1.
实施例3牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Embodiment 3 Oyster calcium carbonate chewable tablet, by every ten thousand pieces of prescription quantity (kg), comprises the following components:
该牡蛎碳酸钙咀嚼片的制备工艺,与实施例1的制备工艺相同。The preparation process of the oyster calcium carbonate chewable tablet is the same as that of Example 1.
实施例4牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Embodiment 4 The oyster calcium carbonate chewable tablet, according to the prescription quantity (kg) of every 10,000 tablets, comprises the following components:
该牡蛎碳酸钙咀嚼片的制备工艺,与实施例1的制备工艺相同。The preparation process of the oyster calcium carbonate chewable tablet is the same as that of Example 1.
实施例5牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Embodiment 5 The oyster calcium carbonate chewable tablet, according to the prescription quantity (kg) of every 10,000 tablets, includes the following components:
该牡蛎碳酸钙咀嚼片的制备工艺,与实施例1的制备工艺相同。The preparation process of the oyster calcium carbonate chewable tablet is the same as that of Example 1.
对比例1牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Comparative Example 1 Oyster calcium carbonate chewable tablet, calculated by the prescription amount (kg) per 10,000 tablets, includes the following components:
牡蛎碳酸钙咀嚼片的制备,包括如下步骤:The preparation of oyster calcium carbonate chewable tablet includes the following steps:
(一)牡蛎碳酸钙颗粒的制备(1) Preparation of oyster calcium carbonate particles
a、将牡蛎碳酸钙经过微粉化处理,过200目筛;a. The oyster calcium carbonate is subjected to micronization treatment and passed through a 200-mesh sieve;
b、将羟丙甲纤维素(HPMC)溶于乙醇溶液中,过80目筛,得粘合剂,备用;B, hypromellose (HPMC) is dissolved in ethanol solution, sieves 80 meshes, obtains adhesive, standby;
c、将羟丙甲纤维素(HPMC)、食用色素溶于乙醇溶液中,过80目筛,得隔离包衣液,备用;C, hypromellose (HPMC), food coloring are dissolved in ethanol solution, cross 80 mesh sieves, obtain isolation coating liquid, for subsequent use;
d、将处方量的牡蛎碳酸钙和微晶纤维素混匀后置于制粒包衣锅中,喷入粘合剂,进行顶喷制粒;d, the oyster calcium carbonate and microcrystalline cellulose of the recipe quantity are mixed and placed in the granulation coating pot, sprayed into the adhesive, and carried out top spray granulation;
e、将顶喷制得的物料过20目筛网,剔除大于20目颗粒;e. Pass the material obtained by top spraying through a 20-mesh screen to remove particles larger than 20-mesh;
f、将颗粒置于制粒包衣锅中,喷入隔离包衣液,底喷包衣;f. The granules are placed in the granulation coating pot, sprayed into the isolation coating liquid, and the bottom is sprayed for coating;
g、将包衣后的物料过16目筛网,剔除大于16目颗粒,得颗粒I;g, the material after coating is crossed 16 mesh screen, rejects more than 16 mesh granules, obtains granule I;
(二)枸橼酸颗粒的制备(2) Preparation of Citric Acid Granules
a、将处方量的枸橼酸、甘露醇、蔗糖粉碎过80目筛;A, the citric acid, mannitol and sucrose of the recipe quantity are pulverized through 80 mesh sieves;
b、将处方量的食用香精、食用色素、谷氨酸钠溶于乙醇溶液中,备用;b. Dissolve the edible essence, food coloring, and sodium glutamate of the prescription in the ethanol solution for subsequent use;
c、将处理后的枸橼酸、甘露醇、蔗糖置入高速制粒机中,慢速搅拌2分钟内,加入含有助剂的乙醇溶液,快速制粒3分钟;c. Put the treated citric acid, mannitol and sucrose into a high-speed granulator, stir at a slow speed for 2 minutes, add an ethanol solution containing an auxiliary agent, and quickly granulate for 3 minutes;
d、将湿粒摊盘,送进烘房,采用70~75℃热风干燥5小时;d. Spread the wet granules on a plate, send them to the drying room, and dry them with hot air at 70-75°C for 5 hours;
e、物料过16目筛网,剔除大于16目颗粒,得颗粒II;e. The material is passed through a 16-mesh screen, and the particles larger than 16-mesh are removed to obtain particle II;
(三)压片(3) Tablet pressing
将颗粒I、颗粒II、滑石粉和硬脂酸镁混匀后压片,即得牡蛎碳酸钙咀嚼片1。Mix Granule I, Granule II, talc and magnesium stearate and press into tablets to obtain oyster calcium carbonate chewable tablet 1.
对比例2牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Comparative Example 2 Oyster calcium carbonate chewable tablets, calculated by the prescription amount (kg) per 10,000 tablets, include the following components:
该牡蛎碳酸钙咀嚼片的制备工艺,与对比例1的制备工艺相同。The preparation process of the oyster calcium carbonate chewable tablet is the same as that of Comparative Example 1.
对比例3现有牡蛎碳酸钙咀嚼片,按每万片处方量(kg)计,包括如下组分:Comparative Example 3 Existing oyster calcium carbonate chewable tablets, calculated by the prescription amount (kg) per 10,000 tablets, include the following components:
处方(10000片)Prescription (10000 tablets)
按上述处方,现有牡蛎碳酸钙咀嚼片采用常规的湿法制粒工艺制备而得,其主要包括如下步骤:(1)将处方量的甘露醇、微晶纤维素、蔗糖、牡蛎碳酸钙、枸橼酸混合,采用谷氨酸钠、色素溶水作湿润剂(若不够加乙醇)对混合物料进行高速制粒后,外拌硬脂酸镁、滑石粉、香精后,压片即得。According to the above-mentioned prescription, the existing oyster calcium carbonate chewable tablet adopts conventional wet granulation technology to prepare, and it mainly comprises the following steps: (1) mannitol, microcrystalline cellulose, sucrose, oyster calcium carbonate, citric acid The mixture is mixed with citric acid, sodium glutamate and pigment-dissolved water are used as wetting agents (if not enough to add ethanol), the mixture is granulated at a high speed, and magnesium stearate, talc, and essence are mixed externally, and then pressed into tablets.
稳定性实验:Stability test:
以采用本发明新工艺的实施例1至实施例5制备的牡蛎碳酸钙咀嚼片为实验组,以对比例1、对比例2和采用现有湿法制粒工艺的对比例3制备的牡蛎碳酸钙咀嚼片为对照组,分别进行加速稳定性实验,具体实验数据如下表1所示。Take the oyster calcium carbonate chewable tablet prepared from the embodiment 1 to the embodiment 5 of the novel process of the present invention as the experimental group, with the oyster calcium carbonate prepared by comparative example 1, comparative example 2 and comparative example 3 using the existing wet granulation process Chewable tablets were used as the control group, and accelerated stability experiments were carried out respectively. The specific experimental data are shown in Table 1 below.
表1加速稳定性实验数据汇总Table 1 Summary of accelerated stability experimental data
由上述表1的加速稳定性实验数据可知,采用本发明新工艺制备的牡蛎碳酸钙咀嚼片,加速考察六个月后,硬度及脆碎度变化较原方法有明显改善,可以有效避免因吸潮而引起的质量问题。It can be known from the accelerated stability experimental data of above-mentioned table 1 that adopt the oyster calcium carbonate chewable tablet prepared by the novel process of the present invention, after six months of accelerated investigation, the hardness and friability change are significantly improved compared with the original method, which can effectively avoid the Quality problems caused by tide.
以上对本发明的具体实施例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。The specific embodiments of the present invention have been described above in detail, but they are only used as examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions to the present invention are also within the scope of the present invention. Therefore, equivalent changes and modifications made without departing from the spirit and scope of the present invention should be included within the scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210726510.1A CN115006363A (en) | 2022-06-23 | 2022-06-23 | A kind of oyster calcium carbonate chewable tablet and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210726510.1A CN115006363A (en) | 2022-06-23 | 2022-06-23 | A kind of oyster calcium carbonate chewable tablet and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115006363A true CN115006363A (en) | 2022-09-06 |
Family
ID=83076696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210726510.1A Pending CN115006363A (en) | 2022-06-23 | 2022-06-23 | A kind of oyster calcium carbonate chewable tablet and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115006363A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11313618A (en) * | 1998-05-06 | 1999-11-16 | Yoshio Inoue | Mineral (zinc) formulation for livestock gentle to stomach and its production |
WO2016029496A1 (en) * | 2014-08-29 | 2016-03-03 | 武汉光谷人福生物医药有限公司 | Methosulide tablet and preparation method therefor |
CN106943427A (en) * | 2017-04-12 | 2017-07-14 | 华北制药河北华诺有限公司 | A kind of calcium carbonate granule composition and preparation method thereof |
CN107259580A (en) * | 2017-07-17 | 2017-10-20 | 武汉维奥制药有限公司 | The preparation method of one kind of multiple mineral matter vitamin preparations |
US20180296526A1 (en) * | 2015-10-07 | 2018-10-18 | Kyowa Hakko Kirin Co., Ltd. | A pharmaceutical composition containing an arylalkylamine compound |
CN110123774A (en) * | 2012-02-21 | 2019-08-16 | 埃斯蒂维制药有限公司 | The combination of oral medication of dabigatran etcxilate |
JP2020147529A (en) * | 2019-03-13 | 2020-09-17 | 東和薬品株式会社 | Preparation containing dabigatran etexilate and stabilization method |
CN112294769A (en) * | 2020-10-27 | 2021-02-02 | 浙江诺得药业有限公司 | Candesartan cilexetil orally disintegrating tablet and preparation method thereof |
CN114010607A (en) * | 2021-10-12 | 2022-02-08 | 上海腾瑞制药股份有限公司 | Preparation method of oyster calcium carbonate chewable tablets |
-
2022
- 2022-06-23 CN CN202210726510.1A patent/CN115006363A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11313618A (en) * | 1998-05-06 | 1999-11-16 | Yoshio Inoue | Mineral (zinc) formulation for livestock gentle to stomach and its production |
CN110123774A (en) * | 2012-02-21 | 2019-08-16 | 埃斯蒂维制药有限公司 | The combination of oral medication of dabigatran etcxilate |
WO2016029496A1 (en) * | 2014-08-29 | 2016-03-03 | 武汉光谷人福生物医药有限公司 | Methosulide tablet and preparation method therefor |
US20180296526A1 (en) * | 2015-10-07 | 2018-10-18 | Kyowa Hakko Kirin Co., Ltd. | A pharmaceutical composition containing an arylalkylamine compound |
CN106943427A (en) * | 2017-04-12 | 2017-07-14 | 华北制药河北华诺有限公司 | A kind of calcium carbonate granule composition and preparation method thereof |
CN107259580A (en) * | 2017-07-17 | 2017-10-20 | 武汉维奥制药有限公司 | The preparation method of one kind of multiple mineral matter vitamin preparations |
JP2020147529A (en) * | 2019-03-13 | 2020-09-17 | 東和薬品株式会社 | Preparation containing dabigatran etexilate and stabilization method |
CN112294769A (en) * | 2020-10-27 | 2021-02-02 | 浙江诺得药业有限公司 | Candesartan cilexetil orally disintegrating tablet and preparation method thereof |
CN114010607A (en) * | 2021-10-12 | 2022-02-08 | 上海腾瑞制药股份有限公司 | Preparation method of oyster calcium carbonate chewable tablets |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE53543B1 (en) | New oral dipyridamole preparations | |
JP2000103731A (en) | Rapid disintegrative solid preparation | |
CN105496977A (en) | Succinic acid trelagliptin orally-disintegrating tablets and preparing method thereof | |
CN101198319A (en) | Granular preparation containing biguanide compound | |
CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
CN109010361B (en) | Calcichew D3 preparation and preparation method thereof | |
CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
RU2563190C2 (en) | Medication based on dry extracts of medicinal plants and method of obtaining thereof (versions) | |
CN115006363A (en) | A kind of oyster calcium carbonate chewable tablet and preparation method thereof | |
CN100546571C (en) | Sangju effervescent tablet for treating common cold | |
CN102058878A (en) | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof | |
CN111617042A (en) | Composite calcium carbonate vitamin D3Water-free swallow granule and preparation method thereof | |
CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
CN110881555A (en) | Dispersible candy tablet with dual-effect of lowering blood pressure | |
RU2260440C1 (en) | Method for preparing preparation "alloocholum" | |
CN101495101B (en) | Sugar-coated preparation and its manufacturing method | |
RU2589507C1 (en) | Agent based on dry motherwort extract and method for production thereof | |
CN108785268A (en) | A kind of Betapace and preparation method thereof | |
US5077294A (en) | Products containing verapamil or gallopamil and prazosin | |
CN103432082A (en) | Glucosamine composition and preparation method thereof | |
WO2006000137A1 (en) | Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof | |
CN101081227B (en) | Composition of diammonium glycyrrhizinate | |
CN101292977A (en) | Pharmaceutical combination with stable strontium ranelate and its preparations | |
CN1209100C (en) | Preparation of durable Chinese medicine and healthy food effervescent tablets | |
CN1303979C (en) | Preparation of snake gallbladder and tangerine peel dispersed tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220906 |